So FCR, so good.
In this issue of Blood, Rossi et al show that certain predictive biomarkers are able to identify a subgroup of patients with chronic lymphocytic leukemia (CLL) who have an exceptionally good outcome following front-line therapy with the combination of fludarabine, cyclophosphamide, and rituximab (FCR).